Fauci AS, Wolff SM. Wegener’s granulomatosis: studies in eighteen patients and a review of the literature. Medicine. 1973;52:535–61.
Article
CAS
PubMed
Google Scholar
Leandro MJ, de la Torre I. Translational mini-review series on B cell directed therapies: the pathogenic role of B cells in autoantibody-associated autoimmune diseases – lessons from B cell-depletion therapy. Clin Exp Immunol 2009:doi:10.1111/j.1365-2249.2009.03977.x
Jones RB, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–20.
Article
CAS
PubMed
Google Scholar
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32.
Article
CAS
PubMed
PubMed Central
Google Scholar
Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771–80.
Article
PubMed
Google Scholar
Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology. 2013;52:2041–7.
Article
CAS
PubMed
Google Scholar
Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology 2014; doi:10.1093/rheumatology/keu452.
Besada E, Koldingsnes W, Nossent JC. Serum immunoglobulin levels and risk factors for hypogammaglobulinemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology. 2014;53:1818–24.
Article
PubMed
Google Scholar
Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. Plos ONE 7(5):e37626. doi:10.1371/journal.pone.0037626.
Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med. 2005;257:540–8.
Article
CAS
PubMed
Google Scholar
Keogh KA, Ytterberg SR, Fervenza FC, Carlsson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006;173:180–7.
Article
CAS
PubMed
Google Scholar
Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60:2156–68.
Article
CAS
PubMed
Google Scholar
Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody –associated vasculitis. Clin J Am Soc Nephrol. 2010;5:1394–400.
Article
CAS
PubMed
PubMed Central
Google Scholar
Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71:327–33.
Article
CAS
PubMed
Google Scholar
Pullerits R, Ljevak M, Vikgren J, Bokarewa M. Off-trial evaluation of the B-cell targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre. Scand J Immunol. 2012;76:411–20.
Article
CAS
PubMed
Google Scholar
Wendt M, Gunnarsson I, Bratt J, Bruchfeld A. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scand J Rheumatol. 2012;41:116–9.
Article
CAS
PubMed
Google Scholar
Turner-Stokes T, Sandhu E, Pepper RJ, Stolagiewicz NE, Ashley C, Dinneen D, et al. Induction treatment of ANCA-associated vasculitis with a single dose of rituximab. Rheumatology. 2014;53:1395–403.
Article
CAS
PubMed
Google Scholar
Moog P, Probst M, Kuechle C, Hauser C, Heemann U, Thuermel K. Single-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: a retrospective analysis of 17 patients. Scand J Rheumatol. 2014;43:519–23.
Article
CAS
PubMed
Google Scholar
Azar L, Springer J, Langford CA, Hoffman GS. Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener’s). Arthritis Rheum. 2014;66:2862–70.
Article
CAS
Google Scholar
Taylor S, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum. 2009;60:1540–7.
Article
PubMed
Google Scholar
Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Russo A, et al. Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis. Am J Nephrol. 2011;34:175–80.
Article
CAS
PubMed
Google Scholar
Mansfield N, Hamour S, Habib AM, Tarzi R, Levy J, Griffith M, et al. Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant. 2011;26:3280–6.
Article
CAS
PubMed
Google Scholar
Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, et al. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol. 2012;39:2153–6.
Article
CAS
PubMed
Google Scholar
Venhoff N, Niessen L, Kreuzaler M, Rolink AG, Hässler F, Rizzi M, et al. Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease. Autoimmunity. 2014;47:401–8.
Article
CAS
PubMed
Google Scholar
Rees F, Yazdani R, Lanyon P. Long-term follow-up of different refractory systemic vasculitides treated with rituximab. Clin Rheumatol. 2011;30:1241–5.
Article
PubMed
Google Scholar
Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, Grasland A, Zoulim A, Le Guen J, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol. 2012;39:125–30.
Article
CAS
PubMed
Google Scholar
Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:3760–9.
Article
CAS
PubMed
Google Scholar
Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sanchez-Menendez M, Ytterberg SR, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s). Arthritis Rheum. 2012;64:3770–8.
Article
CAS
PubMed
Google Scholar
Pendergraft III WF, Cortazar FB, Wenger J, Murphy AP, Rhee EP, Laliberte KA, et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol. 2014;9:736–44.
Article
CAS
PubMed
PubMed Central
Google Scholar
Calich AL, Puéchal X, Pugnet G, London J, Terrier B. Charles P et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener’s). Results of a single-center cohort study on 66 patients. J Autoimmun. 2014;50:135–41.
Knight A, Hallenberg H, Baecklund E. Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis — a case series. Clin Rheumatol. 2014;33:841–8.
Article
CAS
PubMed
Google Scholar
Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, et al. Rituximab for induction and maintenance of ANCA associated vasculitides: a multicenter retrospective study on 80 patients. Rheumatology. 2014;53:532–9.
Article
CAS
PubMed
Google Scholar
Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Rituximab-associated hypogammaglobulinemia: Incidence, predictors ad outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60–5.
Article
CAS
PubMed
Google Scholar